Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Alopecia Areata

Alopecia Areata

Part of Androgenetic alopecia

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Alopecia Areata

34 trials tracked for Alopecia Areata: 10 in phase 3 or 4 and 7 with published results. The most-cited published study has 729 citations.

34Trials tracked
10Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 3 Phase 3 7 Phase 2 19 Phase 1 1 Other / NA 4
  1. Phase 4 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Completed · 729 cited
  2. Phase 3 A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Completed · 37 cited
  3. Phase 3 Long-Term PF-06651600 for the Treatment of Alopecia Areata Completed · 24 cited
  4. Phase 3 PF-06651600 for the Treatment of Alopecia Areata Completed · 21 cited
  5. Phase 3 A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Completed · 19 cited
  6. Phase 4 Pain Outcomes Following Intralesional Corticosteroid Injections Completed · 9 cited
Show 28 more trials
  1. Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) Completed · 4 cited
  2. Phase 4 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed
  3. Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) Completed
  4. Phase 3 European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata Completed
  5. Phase 2 Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata Completed
  6. Phase 2 Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata Completed
  7. Phase 2 Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata Completed
  8. Phase 2 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) Completed
  9. Phase 2 Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata Completed
  10. Phase 2 A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata Completed
  11. Phase 2 Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata Completed
  12. Phase 2 Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata Completed
  13. Phase 2 Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata Completed
  14. Phase 2 Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata Completed
  15. Phase 2 Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata Completed
  16. Phase 2 Tofacitinib for Immune Skin Conditions in Down Syndrome Completed
  17. Phase 2 An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata Completed
  18. Phase 2 A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata Completed
  19. Phase 2 Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Completed
  20. Phase 2 LEO 124249 Ointment in the Treatment of Alopecia Areata Completed
  21. Phase 2 Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata Completed
  22. Phase 2 Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants Completed
  23. Phase 2 Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata Completed
  24. Phase 1 A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age Completed
  25. N/A Tofacitinib for the Treatment of Alopecia Areata and Its Variants Completed
  26. N/A Healthcare Disparities in Alopecia Areata Completed
  27. N/A Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata Completed
  28. N/A Alefacept in Patients With Severe Scalp Alopecia Areata Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Upadacitinib Treatment for Concurrent Atopic Dermatitis Vitiligo and Alopecia Areata
Cardiology Sys. Review
Upadacitinib Treatment for Concurrent Atopic Dermatitis Vitiligo and Alopecia Areata One drug improved skin, hair, and pigment in one man
A 57-year-old man with severe, refractory skin conditions showed significant improvement in dermatitis, vitiligo, and hair loss on upadaciti…
A single patient with three skin conditions saw dramatic improvement after taking upadacitinib for one year.
Frontiers Jun 9, 2026
Systematic review and meta-analysis on alopecia areata and skin cancer risk
Oncology Meta-analysis
Systematic review and meta-analysis on alopecia areata and skin cancer risk Alopecia areata patients may have lower risk of certain skin cancers based on new review data
This systematic review and meta-analysis synthesized eight studies on skin cancer risk in patients with alopecia areata. The analysis found …
This review found that people with hair loss might have a lower chance of getting melanoma. Other skin cancers showed a similar trend but th…
Frontiers May 11, 2026
Autoimmune Thyroiditis Prevalence Higher in Obese Women With PCOS in Retrospective Cohort Analysis
OB/GYN & Women's Health Cohort
Autoimmune Thyroiditis Prevalence Higher in Obese Women With PCOS in Retrospective Cohort Analysis New PCOS Data Reveals Hidden Thyroid Risks
This retrospective cohort study evaluated 1,249 women with PCOS aged 18–44 years.
Women with PCOS should check their thyroid health regularly.
Frontiers Apr 22, 2026
Baricitinib maintains SALT score ≤20 in adults with severe alopecia areata over 152 weeks
Drug Pipeline RCT
Baricitinib maintains SALT score ≤20 in adults with severe alopecia areata over 152 weeks Baricitinib maintained hair regrowth in severe alopecia areata for over three years in this trial
This phase 3 RCT evaluated continuous baricitinib in 196 adults with severe alopecia areata.
Baricitinib kept hair growing on the scalp, eyebrows, and eyelashes for over three years in adults with severe alopecia areata who responded…
Apr 18, 2026
Deuruxolitinib 8 or 12 mg BID improved SALT20 response versus placebo in severe alopecia areata
Drug Pipeline RCT
Deuruxolitinib 8 or 12 mg BID improved SALT20 response versus placebo in severe alopecia areata Hair Regrowth Drug Shows Strong Results in Major Trial
This Phase 3 randomized, double-blind, placebo-controlled, multicenter trial enrolled 517 adults aged 18 to 65 years with severe chronic alo…
A new drug helped 38% of adults with severe hair loss regrow most of their hair in just six months during a major trial.
Apr 17, 2026
Phase 2 trial finds topical STS01 1% improves SALT scores in patchy alopecia areata
Dermatology RCT
Phase 2 trial finds topical STS01 1% improves SALT scores in patchy alopecia areata A New Topical Treatment Shows Promise for Patchy Hair Loss
A phase 2 randomized controlled trial in 155 adults with mild to moderate patchy alopecia areata found that daily topical STS01 1% for 6 mon…
A new, easy-to-apply cream could offer a much-needed treatment option for a common and distressing form of autoimmune hair loss.
medRxiv Apr 11, 2026
Centralized hair loss measurement showed better agreement and 50% lower error margins than local rating in mild-to-moderate Alopecia Areata
Dermatology Phase II
Centralized hair loss measurement showed better agreement and 50% lower error margins than local rating in mild-to-moderate Alopecia Areata Centralized hair loss scoring showed better consistency than local ratings in mild Alopecia Areata trials
This Phase 2 clinical trial compared centralized measurement of hair loss via standardized photographic images against local SALT score rati…
Centralized hair loss scoring cut measurement errors by half compared to local ratings in mild Alopecia Areata trials, boosting trial succes…
medRxiv Apr 6, 2026
Phase 2 trial: Topical STS01 shows dose-related hair regrowth in mild-moderate alopecia areata
Dermatology RCT
Phase 2 trial: Topical STS01 shows dose-related hair regrowth in mild-moderate alopecia areata Topical treatment shows hair regrowth in alopecia areata, but quality of life unchanged
A Phase 2 randomized controlled trial in patients with mild to moderate patchy alopecia areata found that topical STS01 (dithranol) produced…
A new topical treatment regrows hair in patchy alopecia, yet patients report no improvement in daily life or feelings even with full regrowt…
medRxiv Apr 4, 2026
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients
Dermatology Phase III
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients Phase 3 trial tests low-dose IL-2 for severe alopecia areata, results pending
A Phase 3, prospective, randomized, double-blind, multicenter trial compared low-dose IL-2 to placebo in 44 patients with severe alopecia ar…
A major late-stage trial testing low-dose IL-2 for severe alopecia areata has finished, but results on hair regrowth are not yet available.
CT.gov Mar 30, 2026

Research across Androgenetic alopecia

Related studies from across the Androgenetic alopecia family.

Pilot Study Shows 2% Salicylic Acid Shampoo Reduces Scab Severity in Androgenetic Alopecia Patients
Rheumatology Cohort
Pilot Study Shows 2% Salicylic Acid Shampoo Reduces Scab Severity in Androgenetic Alopecia Patients Simple wash removes scabs after hair transplant surgery
This prospective, multicenter, single-arm pilot study evaluated 21 male patients using a 2% salicylic acid shampoo.
A new shampoo formula helps clear scabs after hair transplant surgery without causing pain or irritation for most patients.
Frontiers May 1, 2026

Questions about Alopecia Areata

Is the topical treatment STS01 effective for patchy alopecia areata?

Yes, a phase 2 trial found that topical STS01 1% significantly improved hair regrowth in patchy alopecia areata compared to placebo.

Full answer →
Does having alopecia areata increase or decrease my risk of getting skin cancer?

Alopecia areata is linked to a lower risk of melanoma and possibly other skin cancers, not an increased risk.

Full answer →